Biotech
Guardant Health
Guardant Health raises $360M Series F at $12B valuation
$360M
Total Raised
Series F
Latest Round
2012
Founded
1400+
Employees
505 Penobscot Drive, Redwood City, CA 94063
1 min read
Quick Facts
Valuation
$12B
Latest Round Size
$360M
Latest Round Date
May 2024
Guardant Health: Series F Funding Round
Guardant Health has successfully raised $360M in Series F funding, reaching a valuation of $12B.
Company Overview
Liquid biopsy cancer detection
Funding Details
The Series F round was led by SoftBank Vision Fund, with participation from Baillie Gifford, T. Rowe Price, Khosla Ventures, Sequoia Capital.
Company Information
- Headquarters: 505 Penobscot Drive, Redwood City, CA 94063
- Founded: 2012
- Employees: 1400+
- Category: Biotech
Investment
Guardant Health plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series F
- Baillie Gifford: Verified investor in Series F
- T. Rowe Price: Verified investor in Series F
- Khosla Ventures: Verified investor in Series F
- Sequoia Capital: Verified investor in Series F
Key Investors
SoftBank Vision Fund
Lead Investor
Verified investor in Series F
Baillie Gifford
Investor
Verified investor in Series F
T. Rowe Price
Investor
Verified investor in Series F
Khosla Ventures
Investor
Verified investor in Series F
Sequoia Capital
Investor
Verified investor in Series F
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M